Normal melanocyte differentiation antigens (MDA)

Normal melanocyte differentiation antigens (MDAs) are a group of lineage-specific proteins primarily involved in the biosynthesis of melanin and the structural formation of melanosomes within melanocytes. Key members of this group include MART-1 (Melan-A), gp100 (PMEL), tyrosinase, and tyrosinase-related proteins 1 and 2 (TRP-1 and TRP-2) [1, 2]. While these antigens are expressed in healthy pigmented cells of the skin, eye, and inner ear, they are frequently overexpressed in cutaneous and uveal melanomas, making them significant targets for cancer immunotherapy [2, 4]. Therapeutic strategies targeting MDAs include the use of bispecific T-cell engagers like tebentafusp, which targets a gp100-derived peptide presented by HLA-A*02:01 to redirect T-cell cytotoxicity against tumor cells [3]. Other approaches encompass peptide-based vaccines and adoptive T-cell therapies (TCR-T) designed to exploit the high tumor-to-normal expression ratio of these proteins. However, because MDAs are also present in normal melanocytes, treatment can lead to "on-target, off-tumor" toxicities, most commonly manifesting as vitiligo, uveitis, or hearing impairment due to the autoimmune destruction of healthy pigmented cells [2, 3]. [1] Kawakami Y, et al. (1994) PNAS; [2] Bakos RM, et al. (2010) An Bras Dermatol; [3] Nathan P, et al. (2021) NEJM; [4] Vigneron N. (2015) BioMed Res Int.

Other names

Melanoma-associated differentiation antigensMelanocyte-specific antigensLineage-specific differentiation antigensMelanocyte differentiation antigens

Immune system activation via T-cell receptor (TCR) engagement, bispecific T-cell redirection, or antibody-drug conjugate (ADC) mediated cytotoxicity.